Novartis AG ADR (NVS)vsRevvity Inc. (RVTY)
NVS
Novartis AG ADR
$161.52
-1.40%
HEALTHCARE · Cap: $303.67B
RVTY
Revvity Inc.
$151.60
-3.44%
HEALTHCARE · Cap: $17.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1870% more annual revenue ($57.36B vs $2.91B). NVS leads profitability with a 17.5% profit margin vs 8.2%. RVTY appears more attractively valued with a PEG of 0.73. RVTY earns a higher WallStSmart Score of 52/100 (C-).
NVS
Hold48
out of 100
Grade: D+
RVTY
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.52
$65.96 premium
Intrinsic value data unavailable for RVTY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
1.3% revenue growth
1.2% earnings growth
ROE of 3.3% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : RVTY
The strongest argument for RVTY centers on PEG Ratio, Price/Book. PEG of 0.73 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : RVTY
The primary concerns for RVTY are Revenue Growth, EPS Growth, Return on Equity. A P/E of 76.0x leaves little room for execution misses.
Key Dynamics to Monitor
RVTY carries more volatility with a beta of 1.06 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVTY scores higher overall (52/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Revvity Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?